[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"her2-metastatic-breast-cancer-mbc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:her2-metastatic-breast-cancer-mbc":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100591689","patient-navigation-for-her2-metastatic-breast-cancer-patients-treated-with-tucatinib-100591689",false,"NCT06983691","Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib","Evaluating a Patient Navigation Program to Improve Therapy Management for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib","Inclusion Criteria:\n\n* female (sex assigned at birth);\n* ≥18 years of age at enrollment;\n* diagnosed with HER2+ metastatic breast cancer (mBC);\n* receiving treatment with tucatinib combined with capecitabine and trastuzumab;\n* able to speak and read English\n\nExclusion Criteria:\n\n* visual or hearing impairment;\n* severe cognitive impairment;\n* severe mental illness interfering with ability to participate","FEMALE","18 Years",{"count":19,"type":20},26,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this study is to test a novel nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer (mBC) receiving tucatinib, trastuzumab, and capecitabine. The program will focus on enhancing understanding of the treatment regimen, managing symptoms and adherence, and improving coping and self-management skills. If successful, the program could be integrated into clinical care to better support mBC patients. The main question the study aims to answer is: is the patient navigation program feasible and acceptable for mBC patients?\n\nParticipants will receive patient navigation sessions over about 6 weeks. Participants will also complete study assessments via electronic survey at baseline and at about 3 and 6 weeks after enrollment, with the last assessment occurring after completion of the patient navigation program sessions. Participants will also complete a post-program exit interview.",[26],"HER2+ Metastatic Breast Cancer (MBC)",[28],"Patient Navigation","NOT_YET_RECRUITING","2026-08-05",{"date":32,"type":33},"2026-08-07","ACTUAL",{"date":35,"type":20},"2026-08",{"date":37,"type":20},"2027-03",{"name":39,"class":40},"Duke University","OTHER"]